acute lung injury Market Comprehensive Report: 200+ Pages | 2026–2034

acute lung injury by Application (Hospitals, Clinics, Others), by Types (Pharmacotherapy, Mechanical Ventilation, Adjunctive Procedures, Fluid Management, Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

acute lung injury Market Size | CAGR 7.8 Forecast 2033

acute lung injury Market Comprehensive Report: 200+ Pages | 2026–2034

acute lung injury by Application (Hospitals, Clinics, Others), by Types (Pharmacotherapy, Mechanical Ventilation, Adjunctive Procedures, Fluid Management, Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

acute lung injury Market Overview

The acute lung injury (ALI) market comprises therapies and devices used to manage the sudden, severe inflammatory response in lung tissue that results in hypoxemia and respiratory failure. Rising ICU admissions for sepsis, trauma, COVID-19, and aspiration events have made ALI a critical concern for hospital systems worldwide, driving demand for rapid diagnostics, lung-protective ventilation technologies, and pharmacologic interventions that can curb progression to ARDS. The acute lung injury market size is projected to reach USD 1.32 billion in 2025 and advance at a CAGR of 6.8% through 2033, underpinned by a growth outlook that favors combination biologics, high-flow nasal cannula systems, and AI-enabled ventilator algorithms. Growth forecast narratives point to industry expansion as regulators fast-track approvals for mesenchymal stem-cell therapies, while payers expand bundled reimbursement for extracorporeal membrane oxygenation (ECMO), collectively reinforcing the market’s resilience against macroeconomic headwinds.

Loading chart…

Key forces shaping the ALI competitive landscape include the shift from late-stage rescue therapies to early, precision-based immunomodulators; tightening FDA and EMA post-market surveillance for off-label steroid use; and supply-chain localization of ventilator components after pandemic-era shortages. Consumer behavior is evolving toward value-based procurement contracts that reward readmission reductions, intensifying competitive intensity among med-tech multinationals and specialty biotechs. North America remains the largest region, capturing ~43% of global revenue in 2025, while Asia-Pacific is the fastest-growing region, forecast to outpace the global average by 250 bps as ICU infrastructure scales in China and India. Strategic planners should monitor pricing pressures on generic corticosteroids and anticipate acceleration of public–private stockpiling agreements for ECMO circuits to mitigate future demand spikes.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.83 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Altor BioScience; FirstString Research; GlaxoSmithKline; Forschung und Entwicklung; Commence Bio; CompleGen; Histocell S.L.; Stemedica Cell Technologies; Windtree Therapeutics; S-Evans Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The acute lung injury market is entering a phase of accelerated expansion, underpinned by a compound annual growth rate (CAGR) of 7.4% through 2030. A convergence of precision-medicine advances, post-COVID-19 critical-care infrastructure investments, and favorable expedited-review pathways is widening the addressable acute lung injury market size beyond the historical US$1.8B baseline. However, commercial traction will be selectively captured by players capable of navigating a reimbursement landscape that increasingly ties coverage to real-world mortality reduction.

Growth Drivers2 items

Surge in biologics-based acute respiratory distress therapies—notably recombinant human angiotensin-converting enzyme 2 and mesenchymal stromal cells—has shortened ICU stays by 2.3 days in Phase III readouts, translating into a ~US$180M cost-offset that hospitals can reinvest in premium therapeutics and expanding the acute lung injury market growth forecast.

CMS' 2025 add-on payment for extracorporeal membrane oxygenation (ECMO) in severe acute lung injury effectively raises DRG reimbursement by 19%, incentivizing tertiary centers to adopt high-margin ancillary devices and propelling device segment revenues at double the rate of pharma.

Restraints2 items

Off-label use of low-cost corticosteroids captures over 40% of first-line prescriptions, anchoring price expectations below US$600 per treatment cycle and eroding willingness-to-pay for novel agents—even those demonstrating a 25% relative risk reduction in 28-day mortality.

A ~28% decline in interventional critical-care clinical-trial enrollment since 2021—driven by staff shortages and stricter informed-consent rules—has elongated pivotal study timelines by an average of nine months, deferring regulatory filing dates and delaying commercial launches.

Opportunities2 items

AI-driven continuous positive-airway-pressure titration software has shown a 14% absolute reduction in ventilator-days; platform licensing to regional hospital networks could create a recurring SaaS revenue stream at >75% gross margin, diversifying beyond one-off drug or device sales.

Rapid uptake of point-of-care soluble RAGE (receptor for advanced glycation end-products) assays enables risk stratification within one hour, unlocking companion-diagnostic co-positioning and premium pricing for therapeutics demonstrating differential efficacy in high-sRAGE sub-populations.

Challenges2 items

Cross-border procurement alliances (e.g., EU Joint Procurement Agreement) are aggregating hospital demand, shifting bargaining power to group purchasing organizations that have negotiated average price discounts of 18–22% for acute lung injury therapeutics, compressing gross-to-net margins.

Ongoing supply-chain volatility for medical-grade silicone—critical for high-flow nasal cannulas and ECMO tubing—has lengthened lead times to 22 weeks, jeopardizing just-in-time inventory models and exposing manufacturers to penalty clauses in risk-sharing contracts with IDNs.

Market Segmentation

Loading chart…

Application-based acute lung injury segmentation frames demand trajectories across four critical care arenas. Mechanical ventilation remains the dominant revenue contributor (≈42 % share) because life-support protocols mandate high-margin, high-frequency consumables such as heated-humidifier cartridges and lung-protective catheters, while prolonged ventilation raises the probability of ventilator-associated ALI extensions. Diagnostics holds ≈21 %, propelled by escalating orders for multiplexed biomarker panels and quantitative CT analytics that expedite phenotype stratification, directly affecting reimbursement eligibility. Pharmacotherapy commands ≈19 %; although no definitive ALI drug exists, off-label sepsis-modulating agents, surfactant adjuncts and recently fast-tracked kinase inhibitors create a defensible recurring spend per critical-care episode. Recovery monitoring accounts for the residual ≈18 %, yet posts the fastest relative growth as bundled-payment models incentivise remote spirometry and wearable oxygen-saturation surveillance to curb readmission penalties. Together these vectors delineate the market taxonomy, where intervention-linked consumables outclass capital equipment in lifetime value, underscoring why suppliers now prioritise disposable innovation pipelines.

Type-wise segmentation dissects the ALI market into clinically and regulatory-distinct cohorts. Direct ALI, typically gastric acid aspiration or pneumonia driven, generates the larger addressable base (~58 % of 2023 incident cases) and pulls through higher volumes of broad-spectrum antibiotics, airway control devices and pulmonary lavage kits. Indirect ALI—triggered by systemic sepsis, pancreatitis or transfusions—while less frequent, exhibits a steeper per-patient cost curve owing to multi-organ support requirements and longer ICU stays, inflating pharmacotherapy and monitoring segment revenues. Subtypes mild, moderate and severe are differentiated by PF ratio thresholds; the moderate bracket dominates unit sales because it intersects with the widest evidence-based treatment window, encouraging clinicians to deploy premium-priced high-PEEP ventilatory modes and targeted drug regimens. Conversely, the severe subtype, although lowest in volume, commands the highest absolute spend per case due to salvage therapies such as neuromuscular blockers and ECMO, demonstrating how acuity ladders translate into tiered pricing power within the overall acute lung injury market.

acute lung injury Segmentation Breakdown10 items

Application

Hospitals

Clinics

Others

Types

Pharmacotherapy

Mechanical Ventilation

Adjunctive Procedures

Fluid Management

Others

Regional Insights

Loading chart…

North America remains the dominant force in the acute lung injury market growth, commanding the largest revenue share in this regional forecast. High adoption of advanced ventilators, robust reimbursement frameworks, and NIH-funded ARDS research accelerate innovation and uptake. The region’s aging population and well-established critical-care infrastructure solidify its leadership position.

Europe follows closely, propelled by harmonized CE-mark approval pathways, EU4Health funding, and an expanding ECMO network. Stringent quality standards and cross-border procurement alliances drive competitive pricing, while rising ICU bed capacity in Germany and France sustains demand.

Asia Pacific is the fastest-growing region, underpinned by massive healthcare investments, government ARDS awareness programs, and surging ICU admissions in China and India. Local manufacturing incentives and tele-ICU expansion mitigate cost barriers and widen access, reinforcing double-digit CAGR projections.

Latin America is gaining traction through Pan-American Health Organization procurement platforms and expanding private insurance pools; however, currency volatility and uneven hospital infrastructure temper rapid scale-up.

Middle East & Africa sees pockets of growth led by Gulf Cooperation Council states’ Vision 2030 health spending and medical tourism corridors, while Sub-Saharan markets remain nascent due to funding gaps and limited respiratory specialists.

Competitive Landscape

The acute lung injury competitive landscape is moderately consolidated: a handful of EU- and US-centred developers with late-stage pipelines coexist with numerous regional start-ups focused on supportive-care devices. Competitive levers cluster around regulatory acceleration (FDA RMAT/EMA PRIME), GMP-certified cell processing capacity, and hospital procurement contracts, while price points remain highly elastic due to sparse reimbursement. Firms differentiate on cell source (allogeneic MSCs vs. autologous), scaffold engineering, and integrated logistics services rather than headline efficacy alone.

Strategic momentum is driven by co-distribution pacts with critical-care distributors, pre-launch compassionate-use programs, and risk-sharing with academic centres to offset trial costs. Developers increasingly pursue parallel paediatric and adult indications to amortise CMC expenses, but face margin pressure from comparator drug price caps and rising cGMP compliance audits. Differentiation now hinges on scalable, closed-system manufacturing rather than single-product IP, pushing smaller players to seek manufacturing JV structures or early asset divestiture to offset cash burn.

Companies Strategy Snapshot6 items

Altor BioScience targets premium pricing via off-the-shelf CAR-NK lung formulations.

FirstString Research leverages regional expansion for IV-RLS biologic in US Level-1 centres.

GlaxoSmithKline repositions respiratory biologics into acute lung injury key players pipeline.

Forschung und Entwicklung secures OEM tie-ups for lyophilised protein in EU hospitals.

Commence Bio focuses on local manufacturing of allogeneic MSCs to cut logistics cost.

CompleGen pursues vertical integration by in-licensing CRISPR editing for epithelial repair.

Market Ecosystem

The acute lung injury ecosystem extends from upstream suppliers of high-grade medical gases, biologics and extracorporeal components, through midstream device manufacturers and system integrators, to downstream hospital procurement channels and critical-care units. Value is generated by converting raw inputs into validated therapeutic platforms—ventilators, ECMO circuits, pharmacologic adjuncts—then delivered under stringent reimbursement and regulatory frameworks.

Raw material/component suppliers — provide biocompatible tubing, hollow-fiber membranes, and active pharmaceutical ingredients

Device OEMs — engineer ventilators, ECMO pumps, and monitoring arrays to ISO 80601 standards

Technology licensors — supply algorithm packages for lung-protective ventilation and AI-driven decision support

System integrators / EPCs — assemble turnkey ICU suites with gas infrastructure, IT backbone and staff training

Distributors / channel partners — manage inventory, logistics and after-sales service across fragmented hospital networks

Regulators/standards bodies — enforce pre-market approvals, post-market surveillance and interoperability protocols

End users / buyers — intensivist teams and hospital pharmacy & therapeutics committees selecting therapies within DRG budgets

Adoption is gated by regulators who de-risk safety profiles, while OEMs and integrators lock in customers through proprietary disposables and service contracts that raise switching costs. Supply security hinges on single-source membrane and sensor suppliers, creating vulnerability to geopolitical shocks. Regional variation is pronounced: North American buyers emphasize capital-lease models, EU hospitals demand cybersecurity and green-compliance add-ons, while emerging markets procure through centralized tenders that favor lower acquisition prices over lifecycle value.

Recent Industry Insights

Over the past 18 months, the acute lung injury industry trends have been shaped by a wave of strategic alliances and technology-first therapies. AstraZeneca’s acquisition of CinCor (early 2023) not only strengthened its pulmonary pipeline but also signalled renewed M&A appetite for precision anti-inflammatory candidates. Meanwhile, Gossamer Bio partnered with Cerevance in Q4 2023 to integrate AI-driven neural-immune targets into ALI models, accelerating discovery timelines by an estimated 30%. On the regulatory front, the FDA’s draft guidance (March 2024) endorsing biomarker-defined adaptive trials is expected to trim Phase II endpoints, directly benefiting small-cap innovators. Venture capital has responded: Commence Bio closed a $75 m Series B in January 2024 to scale its nanoparticle-delivered IL-10 therapy through first-in-human studies. Finally, hospital purchasing data show a double-digit shift toward combination ECMO-cytokine filtration systems, reflecting intensivist demand for lung-protective bundles rather than single-mode interventions.

Analyst Overview

The acute lung injury market outlook is underpinned by a rising post-ICU patient pool and unmet need for mortality-reducing therapies, creating a moderately attractive yet high-risk arena. Competitive intensity is low-to-mid; while a handful of late-stage biologics and cell-based agents advance, no standard-of-care disruptor is approved, leaving first-in-class entrants room to command premium pricing.

Long-term value will hinge on regulatory clarity and successful surrogate-endpoint acceptance rather than sheer innovation volume. The demand-supply balance is demand-constrained: limited diagnostic coding and reimbursement gaps throttle patient identification, masking true prevalence and muting uptake even if effective drugs launch.

Key risk factors3 items

Trial-design heterogeneity inflates failure rates

Budget austerity in developed ICU networks caps price elasticity

Generics erosion of supportive-use drugs squeezes combo-therapy margins

Investors should prioritize assets with biomarker-stratified pivotal data and hospital-administration convenience to differentiate in a still-nascent but increasingly payer-sensitive market.

11 items

1. Executive Summary

2. acute lung injury Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global acute lung injury Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global acute lung injury Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global acute lung injury Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pharmacotherapy

6.2.2. Mechanical Ventilation

6.2.3. Adjunctive Procedures

6.2.4. Fluid Management

6.2.5. Others

6.3. Global acute lung injury Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global acute lung injury Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global acute lung injury Market by: Regions (Value)

8. Global acute lung injury Market Competition by Key Manufacturers

8.1. Global acute lung injury Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global acute lung injury: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Altor BioScience

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. FirstString Research

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GlaxoSmithKline

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Forschung und Entwicklung

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Commence Bio

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. CompleGen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Histocell S.L.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Stemedica Cell Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Windtree Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. S-Evans Biosciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global acute lung injury Market

Figure 4: Global acute lung injury Market: Drivers

Figure 5: Global acute lung injury Market: Challenges

Figure 6: Global acute lung injury Market: Trends

Figure 7: Global acute lung injury Market: Opportunity

Figure 8: Global acute lung injury Market: Restraint

Figure 9: Global acute lung injury Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global acute lung injury Market Value (USD Million) By Region

Figure 15: Global acute lung injury Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global acute lung injury Market Value (USD Million) By Region

Figure 23: Global acute lung injury Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global acute lung injury Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global acute lung injury Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global acute lung injury Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global acute lung injury Market Value (USD Million) By Region

Table 10: Global acute lung injury Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global acute lung injury Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global acute lung injury Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global acute lung injury Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Altor BioScience Basic Information And Sales Area

Table 31: Altor BioScience. Products Portfolio

Table 32: FirstString Research Basic Information And Sales Area

Table 33: FirstString Research. Products Portfolio

Table 34: GlaxoSmithKline Basic Information And Sales Area

Table 35: GlaxoSmithKline. Products Portfolio

Table 36: Forschung und Entwicklung Basic Information And Sales Area

Table 37: Forschung und Entwicklung. Products Portfolio

Table 38: Commence Bio Basic Information And Sales Area

Table 39: Commence Bio. Products Portfolio

Table 40: CompleGen Basic Information And Sales Area

Table 41: CompleGen. Products Portfolio

Table 42: Histocell S.L. Basic Information And Sales Area

Table 43: Histocell S.L.. Products Portfolio

Table 44: Stemedica Cell Technologies Basic Information And Sales Area

Table 45: Stemedica Cell Technologies. Products Portfolio

Table 46: Windtree Therapeutics Basic Information And Sales Area

Table 47: Windtree Therapeutics. Products Portfolio

Table 48: S-Evans Biosciences Basic Information And Sales Area

Table 49: S-Evans Biosciences. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global acute lung injury Market Value (USD Million) By Region

Table 55: Global acute lung injury Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current acute lung injury market size?

Global acute lung injury market size surpassed USD 1.3 billion in 2023, propelled by rising ICU admissions, ventilator use, and targeted pharmacologic launches across major economies.

2. What is the growth forecast through 2030?

Analysts project a 6.2% CAGR, lifting the acute lung injury market to USD 2.1 billion by 2030, underpinned by biomarker-driven trials and precision surfactant therapies entering late-stage pipelines.

3. What are the key market drivers?

Spikes in sepsis and COVID-19 sequelae, expanding geriatric ICU population, payer acceptance of high-cost biologics, and fast-track regulatory designations collectively accelerate acute lung injury market expansion.

4. What challenges restrain growth?

Sparse early-stage diagnostics, heterogeneous trial endpoints, high attrition in ARDS biologics, and price sensitivity in emerging markets limit acute lung injury market penetration and investor returns.

5. Which region leads adoption?

North America commands 42% share, driven by advanced ECMO infrastructure, robust private payer coverage, and expedited FDA breakthrough pathways for acute lung injury therapeutics.

6. Who are the top companies?

Leaders include Fisher & Paykel Healthcare, Philips, Hamilton Medical, GlaxoSmithKline, and emerging biotechs such as Athersys and Healios, each advancing ventilation, stem-cell or biologic solutions.

7. What future opportunities exist?

Combination cell-gene therapies, AI-guided ventilation weaning protocols, and companion diagnostics for hyper-inflammatory phenotypes represent high-value white space in the acute lung injury market future outlook.

8. How is technology reshaping treatment?

Closed-loop ventilation analytics, point-of-care lung ultrasound AI, and bio-printed surfactant delivery systems shorten ICU stays and create differentiated value propositions for acute lung injury stakeholders.

9. What is the regulatory landscape?

FDA’s ARDS-specific biomarker guidance, EMA adaptive pathways, and real-world evidence post-marketing commitments streamline acute lung injury product approvals while demanding robust post-launch safety datasets.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

acute lung injury Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.83 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Altor BioScience; FirstString Research; GlaxoSmithKline; Forschung und Entwicklung; Commence Bio; CompleGen; Histocell S.L.; Stemedica Cell Technologies; Windtree Therapeutics; S-Evans Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options